Clinical Research Directory
Browse clinical research sites, groups, and studies.
BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Summary
This is a prospective, non-inferiority study comparing VRD±D followed by BCMA CAR-T cell therapy versus VRD±D followed by autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma patients.
Official title: A Prospective, Non-inferiority Study Comparing VRD±D Followed by BCMA CAR-T Cell Therapy Versus VRD±D Followed by Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Patients With Newly-diagnosed Multiple Myeloma
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2025-02-05
Completion Date
2030-12
Last Updated
2025-08-03
Healthy Volunteers
No
Conditions
Interventions
anti-BCMA CAR-T
Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.
ASCT
Autologous stem cell infusion
Locations (1)
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
Tianjin, China